Progenitor Cell Therapy, LLC provides contract development and manufacturing services for cell therapy products. The company offers manufacturing solutions; engineering and innovation services; product and process development services; cell and tissue processing; storage, distribution, and delivery of tissues, primary cells, and cell therapy products; and consulting and regulatory support services, such as product and process development, GTP/cGMP manufacturing, regulatory services, and business development and commercialization. It serves academic, biotech, pharmaceutical, and professional clients in the United States. The company was founded in 1997 and is based in Allendale, New Jersey. I...
4 Pearl Court
Allendale, NJ 07401
Founded in 1997
ImmunoCellular Therapeutics Selects PCT, LLC to Manufacture ICT-107 Immunotherapy for Glioblastoma
Jun 15 15
Caladrius Biosciences (CLBS) announced that its subsidiary, PCT, LLC, has been selected by ImmunoCellular Therapeutics (IMUC) as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with Pct LLC for US Production of ICT-107 for Phase 3 Registration Trial
Jun 15 15
ImmunoCellular Therapeutics Ltd. announced the selection of PCT, LLC as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.
Progenitor Cell Therapy Announces Executive Changes
Nov 5 14
NeoStem Inc. announced the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals. Harry Lam, Ph.D. joins NeoStem's subsidiary, Progenitor Cell Therapy (PCT), as Vice President, Manufacturing and Technical Operations, where he will be responsible for overseeing manufacturing operations, engineering, technology transfer, facilities, manufacturing development, and process development. An experienced technical leader, Dr. Lam has over thirty years of biopharmaceutical manufacturing experience. Prior to joining PCT, he spent seventeen years at Genentech, where his advanced degrees in Chemical Engineering allowed him to advance to the position of Roche Global Head of Contract Manufacturing Operations, Commercial Drug Substance. Recently, he was Senior Vice President, Technical Operations, at KaloBios Pharmaceuticals, and Vice President and Head of Manufacturing for Shire Regenerative Medicine. Ann M. Daus, Ph.D. joins PCT as Vice President, Quality, where she will be responsible for establishing and managing all aspects of Quality as related to the regulated (cGMP/GTP) manufacturing of both clinical and commercial cell therapy products including company-wide quality plans and corporate audit programs with participation in regulatory strategies/submissions. An experienced leader with over twenty years of management experience, Dr. Daus brings to PCT a successful track record for effective performance and leadership in the fields of biopharmaceuticals, pharmaceuticals, medical devices, OTC, diagnostics, aseptic filling, blood banking and contract manufacturing. Previously, Dr. Daus served as Vice President, Quality at Laureate Biopharma, and has held various leadership positions at ImClone Systems Incorporated, Smith-Kline Beecham Pharmaceuticals (SKB) and Johnson & Johnson.